KUALA LUMPUR: RHB Research has upgraded Duopharma Biotech to Buy from Sell with a new discounted cashflow-derived target price of RM4 from RM3.30 on the clarity of its Covid-19 vaccine participation in Malaysia.
The research house said on Thursday Duopharma’s prospects of participation in the vaccine had increased significantly after the government’s announcement on Tuesday.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!